Abstract:Background/aims: Previous research has indicated that the currently available histone deacetylase inhibitors (HDACis) are not effective as monotherapies against oral squamous cell carcinoma (OSCC). However, HDACis act synergistically with other therapeutic agents to exert significant antitumor activities. Thus, a strategy to develop chemotherapeutic agents by combining several active groups based on histone deacetylase (HDAC) into a single molecule as a conjugate that modulates multiple cellular pathways may be useful for the treatment of OSCC. Methods: The novel inhibitor Roxyl-ZR was prepared by organic synthesis and its anticancer effects on OSCC were investigated by cell metabolism (n=5), colony formation (n=3), cell cycle (n=3), cell apoptosis (n=3), wound healing (n=3), transwell migration (n=3), and 5-bromo-2'-deoxyuridine staining (n=3) assays in vitro and in in vivo xenograft mice models (4 mice/group for subcutaneous xenograft and 3 mice/group for orthotopic xenograft ). The abundance of Ki67, Bcl-2, and p-STAT3 was detected by immunohistochemistry staining (n=4). Apoptotic cells in the tumor tissues of mice were detected by terminal deoxynucleotidyl transferase dUTP nickend labeling assay (n=3). The abundance of related proteins levels were evaluated by western blot (n=3). E-cadherin expression was detected by an immunofluorescence assay (n=3). Results: Compared with the approved HDACi, conjugated Roxyl-ZR exhibited significantly higher antitumor effects in OSCC cells. Roxyl-ZR suppressed OSCC cell proliferation by inducing the reduction of S phase and inducing caspase-dependent apoptosis by down-regulating Bcl-2 expression. Moreover, Roxyl-ZR attenuated the epithelial-mesenchymal transition, which is closely associated with migration and invasion. In addition, Roxyl-ZR inhibited OSCC xenograft mice models and showed low toxicity. The mechanism underlying the Roxyl-ZR-enhanced sensitivity to HDACi may be attributed to the inhibition of key regulators of JAK1-STAT3 signaling pathway. Conclusion: HDAC-cyclin-dependent kinase conjugates represent a novel approach to the development of OSCC treatment. Our findings may open a new avenue for the development of novel inhibitors for the treatment of OSCC.

Development of lipid nanoparticles for a histone deacetylases inhibitor as a promising anticancer therapeutic

An Integrative Proteome-Based Pharmacologic Characterization and Therapeutic Strategy Exploration of SAHA in Solid Malignancies

Gelated Vorinostat with Inner-Lysosome Triggered Release for Tumor-Targeting Chemotherapy.

Development of new nanoniosome carriers for vorinostat: Evaluation of anticancer efficacy in vitro

A facile route to form self-carried redox-responsive vorinostat nanodrug for effective solid tumor therapy.

Hyaluronic Acid-Coated Cationic Nanostructured Lipid Carriers for Oral Vincristine Sulfate Delivery

Enhanced cellular uptake and cytotoxicity of vorinostat through encapsulation in TPGS-modified liposomes

Hybrid artificial cell-mediated epigenetic inhibition in metastatic lung cancer

Irgd-Decorated Polymeric Nanoparticles for the Efficient Delivery of Vandetanib to Hepatocellular Carcinoma: Preparation and in Vitro and in Vivo Evaluation.

Discovery of a Novel Hybrid of Vorinostat and Riluzole as a Potent Antitumor Agent

Resveratrol loaded functionalized nanostructured lipid carriers for breast cancer targeting: Systematic development, characterization and pharmacokinetic evaluation

Nanomicelles Potentiate HDAC Inhibitor Efficacy In Vitro.

Development of a stable single-vial liposomal formulation for vincristine

Redox-sensitive Iodinated Polymersomes Carrying Histone Deacetylase Inhibitor As a Dual-Functional Nano-Radiosensitizer for Enhanced Radiotherapy of Breast Cancer

Development, optimization, and in vitro evaluation of atorvastatin calcium and vinpocetine codelivery by solid lipid nanoparticles for cancer therapy

Development of Purine-Based Hydroxamic Acid Derivatives: Potent Histone Deacetylase Inhibitors with Marked in Vitro and in Vivo Antitumor Activities

Lenvatinib-valproic acid self nanoemulsifying preconcentrate for the treatment of liver cancer

Enhancement of Histone Deacetylase Inhibitor Sensitivity in Combination with Cyclin-Dependent Kinase Inhibition for the Treatment of Oral Squamous Cell Carcinoma

Design of smart chemotherapy of doxorubicin hydrochloride using nanostructured lipid carriers and solid lipid nanoparticles for improved anticancer efficacy

Novel Copper-Based and Ph-Sensitive Nanomedicine for Enhanced Chemodynamic Therapy.

Pendant HDAC Inhibitor SAHA Derivatised Polymer As a Novel Prodrug Micellar Carrier for Anticancer Drugs